Home › Companies › Neurocrine Biosciences, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Neurocrine Biosciences, Inc.’s Form 8-K, filed May 28, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 27, 2026: 5 items on Neurocrine Biosciences, Inc.’s Form 8-K, filed May 28, 2026: 3 elected · 2 approved.
Notable dissent: 3 directors (11.9%, 11.2%, 10.1% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Neurocrine Biosciences, Inc. in the interactive database Compare manager voting policies
These tallies are Neurocrine Biosciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 28, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Kevin C. Gorman, Ph.D. | 76,228,063 | -- | -- | 8,538,217 | 5,352,345 | 90% | Elected | — |
| Elect Director: Gary A. Lyons | 75,278,705 | -- | -- | 9,487,575 | 5,352,345 | 89% | Elected | — |
| Elect Director: Johanna Mercier | 74,671,942 | -- | -- | 10,094,338 | 5,352,345 | 88% | Elected | — |
| The compensation of the Company's named executive officers, as disclosed in the Proxy Statement, was approved on an advisory basis. • Approval of the Amended 2025 Plan. | 79,131,622 | 5,568,926 | 65,732 | -- | 5,352,345 | 93% | Approved | — |
| The Amended 2025 Plan was approved. • Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. | 83,880,185 | 6,170,483 | 67,957 | -- | -- | 93% | Approved | — |
Source: Neurocrine Biosciences, Inc., Form 8-K, filed with the SEC on May 28, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
639 asset managers disclosed a vote on at least one Neurocrine Biosciences, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Neurocrine Biosciences, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 10 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Description as filed by funds: The election of the Board of Directors' three nominees for Class III directors named below to the Board of Directors to serve for a term of three years: Gary A. Lyons
Neurocrine Biosciences, Inc.’s own tally for this item (“Elect Director: Gary A. Lyons”): 75,278,705 for, 9,487,575 withheld, per its Form 8-K filed May 28, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The three nominees for Class III Director were elected.”
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 142 asset managers below reported 38,129,008 for, 2,117,901 withheld, 22 abstained, 98 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,885,373 | 0 | 22 | 0 | For |
| BlackRock | 7,355,109 | 0 | 0 | 0 | For |
| Dodge & Cox | 4,419,163 | 0 | 0 | 0 | For |
| JPMorgan | 3,365,627 | 0 | 0 | 0 | For |
| Fidelity | 2,036,275 | 0 | 0 | 0 | For |
| State Street | 4,869 | 0 | 0 | 1,367,387 | Withhold |
| Victory Capital | 1,303,471 | 0 | 0 | 0 | For |
| First Trust | 948,076 | 0 | 0 | 0 | For |
| Charles Schwab | 887,595 | 0 | 0 | 0 | For |
| Jackson National | 510,881 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 435,679 | 0 | 0 | 0 | For |
| AQR | 433,505 | 0 | 0 | 0 | For |
| TIAA | 416,263 | 0 | 0 | 0 | For |
| Dimensional | 265,368 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 0 | 230,456 | Withhold |
| Equitable | 34,452 | 0 | 0 | 189,377 | Mixed |
| Invesco | 220,128 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 217,899 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 204,682 | Withhold |
| AIG/SunAmerica | 181,727 | 0 | 0 | 0 | For |
| Allspring | 180,991 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 169,230 | 0 | 0 | 0 | For |
| Northwestern Mutual | 148,519 | 0 | 0 | 0 | For |
| Eaton Vance | 144,270 | 0 | 0 | 0 | For |
| Prudential/PGIM | 142,115 | 0 | 0 | 0 | For |
Showing the 25 largest of 142 asset managers. All 142 are in the interactive database (link above).
Combines 10 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: The election of the Board of Directors' three nominees for Class III directors named below to the Board of Directors to serve for a term of three years: Johanna Mercier
Neurocrine Biosciences, Inc.’s own tally for this item (“Elect Director: Johanna Mercier”): 74,671,942 for, 10,094,338 withheld, per its Form 8-K filed May 28, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The three nominees for Class III Director were elected.”
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 142 asset managers below reported 38,161,923 for, 2,084,987 withheld, 21 abstained, 98 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,879,585 | 0 | 21 | 5,789 | For |
| BlackRock | 7,355,109 | 0 | 0 | 0 | For |
| Dodge & Cox | 4,419,163 | 0 | 0 | 0 | For |
| JPMorgan | 3,365,627 | 0 | 0 | 0 | For |
| Fidelity | 2,036,275 | 0 | 0 | 0 | For |
| State Street | 4,938 | 0 | 0 | 1,367,318 | Withhold |
| Victory Capital | 1,303,471 | 0 | 0 | 0 | For |
| First Trust | 948,076 | 0 | 0 | 0 | For |
| Charles Schwab | 887,595 | 0 | 0 | 0 | For |
| Jackson National | 510,881 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 435,679 | 0 | 0 | 0 | For |
| AQR | 433,505 | 0 | 0 | 0 | For |
| TIAA | 416,263 | 0 | 0 | 0 | For |
| Dimensional | 265,368 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 230,456 | 0 | 0 | 0 | For |
| Equitable | 34,452 | 0 | 0 | 189,377 | Mixed |
| Invesco | 220,128 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 217,899 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 204,682 | Withhold |
| AIG/SunAmerica | 181,727 | 0 | 0 | 0 | For |
| Allspring | 180,991 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 169,230 | 0 | 0 | 0 | For |
| Northwestern Mutual | 101,844 | 0 | 0 | 46,675 | Mixed |
| Eaton Vance | 144,270 | 0 | 0 | 0 | For |
| Prudential/PGIM | 142,115 | 0 | 0 | 0 | For |
Showing the 25 largest of 142 asset managers. All 142 are in the interactive database (link above).
Combines 11 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Description as filed by funds: The election of the Board of Directors' three nominees for Class III directors named below to the Board of Directors to serve for a term of three years: Kevin C. Gorman, Ph.D.
Neurocrine Biosciences, Inc.’s own tally for this item (“Elect Director: Kevin C. Gorman, Ph.D.”): 76,228,063 for, 8,538,217 withheld, per its Form 8-K filed May 28, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The three nominees for Class III Director were elected.”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 142 asset managers below reported 38,129,009 for, 2,117,901 withheld, 21 abstained, 98 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,885,374 | 0 | 21 | 0 | For |
| BlackRock | 7,355,109 | 0 | 0 | 0 | For |
| Dodge & Cox | 4,419,163 | 0 | 0 | 0 | For |
| JPMorgan | 3,365,627 | 0 | 0 | 0 | For |
| Fidelity | 2,036,275 | 0 | 0 | 0 | For |
| State Street | 4,869 | 0 | 0 | 1,367,387 | Withhold |
| Victory Capital | 1,303,471 | 0 | 0 | 0 | For |
| First Trust | 948,076 | 0 | 0 | 0 | For |
| Charles Schwab | 887,595 | 0 | 0 | 0 | For |
| Jackson National | 510,881 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 435,679 | 0 | 0 | 0 | For |
| AQR | 433,505 | 0 | 0 | 0 | For |
| TIAA | 416,263 | 0 | 0 | 0 | For |
| Dimensional | 265,368 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 0 | 230,456 | Withhold |
| Equitable | 34,452 | 0 | 0 | 189,377 | Mixed |
| Invesco | 220,128 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 217,899 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 204,682 | Withhold |
| AIG/SunAmerica | 181,727 | 0 | 0 | 0 | For |
| Allspring | 180,991 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 169,230 | 0 | 0 | 0 | For |
| Northwestern Mutual | 148,519 | 0 | 0 | 0 | For |
| Eaton Vance | 144,270 | 0 | 0 | 0 | For |
| Prudential/PGIM | 142,115 | 0 | 0 | 0 | For |
Showing the 25 largest of 142 asset managers. All 142 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
98% of fund votes cast · no official result
Description as filed by funds: To approve an amendment of the Company's 2025 Equity Incentive Plan to increase the aggregate number of shares of common stock reserved for issuance thereunder by 4,000,000 shares; and
The 144 asset managers below reported 39,184,889 for, 975,913 against, 18,713 abstained, 98 not voted. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,874,703 | 10,691 | 0 | 0 | For |
| BlackRock | 7,355,109 | 0 | 0 | 0 | For |
| Dodge & Cox | 4,419,163 | 0 | 0 | 0 | For |
| JPMorgan | 3,365,627 | 0 | 0 | 0 | For |
| Fidelity | 1,790,435 | 245,840 | 0 | 0 | Mixed |
| State Street | 1,370,066 | 2,190 | 0 | 0 | For |
| Victory Capital | 1,303,471 | 0 | 0 | 0 | For |
| First Trust | 948,076 | 0 | 0 | 0 | For |
| Charles Schwab | 887,595 | 0 | 0 | 0 | For |
| Jackson National | 510,881 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 435,679 | 0 | 0 | 0 | For |
| AQR | 433,505 | 0 | 0 | 0 | For |
| TIAA | 416,263 | 0 | 0 | 0 | For |
| Dimensional | 265,368 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 230,456 | 0 | 0 | 0 | For |
| Equitable | 223,829 | 0 | 0 | 0 | For |
| Invesco | 220,128 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 217,899 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 204,682 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 181,727 | 0 | 0 | 0 | For |
| Allspring | 180,991 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 0 | 169,230 | 0 | 0 | Against |
| Northwestern Mutual | 148,519 | 0 | 0 | 0 | For |
| Eaton Vance | 144,270 | 0 | 0 | 0 | For |
| Prudential/PGIM | 142,115 | 0 | 0 | 0 | For |
Showing the 25 largest of 144 asset managers. All 144 are in the interactive database (link above).
Combines 16 wordings of this item as funds reported it.
93% Approved · of votes cast
Description as filed by funds: Advisory vote on the compensation paid to the Company's named executive officers;
Neurocrine Biosciences, Inc.’s own tally for this item (“The compensation of the Company's named executive officers, as disclosed in the Proxy Statement, was approved on an advisory basis. • Approval of the Amended 2025 Plan.”): 79,131,622 for, 5,568,926 against — passed, per its Form 8-K filed May 28, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The compensation of the Company's named executive officers, as disclosed in the Proxy Statement, was approved on an advisory basis.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,885,386 | 9 | 0 | 0 | For |
| BlackRock | 7,355,109 | 0 | 0 | 0 | For |
| Dodge & Cox | 4,419,163 | 0 | 0 | 0 | For |
| JPMorgan | 3,365,627 | 0 | 0 | 0 | For |
| Fidelity | 2,036,275 | 0 | 0 | 0 | For |
| State Street | 1,372,256 | 0 | 0 | 0 | For |
| Victory Capital | 1,303,471 | 0 | 0 | 0 | For |
| First Trust | 948,076 | 0 | 0 | 0 | For |
| Charles Schwab | 887,595 | 0 | 0 | 0 | For |
| Jackson National | 510,881 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 435,679 | 0 | 0 | 0 | For |
| AQR | 433,505 | 0 | 0 | 0 | For |
| TIAA | 416,263 | 0 | 0 | 0 | For |
| Dimensional | 265,368 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 230,456 | 0 | 0 | 0 | For |
| Equitable | 223,829 | 0 | 0 | 0 | For |
| Invesco | 0 | 220,128 | 0 | 0 | Against |
| Manager Directed Portfolios | 217,899 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 204,682 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 181,727 | 0 | 0 | 0 | For |
| Allspring | 180,991 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 169,230 | 0 | 0 | 0 | For |
| Northwestern Mutual | 148,519 | 0 | 0 | 0 | For |
| Eaton Vance | 144,270 | 0 | 0 | 0 | For |
| Prudential/PGIM | 142,115 | 0 | 0 | 0 | For |
Fund voting reports, all 142 managers: 39,844,528 for, 388,206 against, 18,613 abstained, 98 not voted, 121 mixed. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Dodge & Cox | 5,194,063 | 0 | 0 | 0 | For |
| BlackRock | 4,963,475 | 0 | 0 | 0 | For |
| State Street | 3,940,704 | 3,514 | 0 | 0 | For |
| AQR | 2,772,549 | 0 | 0 | 0 | For |
| Two Sigma | 2,133,902 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,121,019 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 1,400,528 | 0 | 0 | Against |
| Wellington | 1,133,580 | 0 | 0 | 0 | For |
| Northern Trust | 1,095,609 | 0 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 1,062,072 | 0 | 0 | 0 | For |
| Renaissance | 1,048,779 | 0 | 0 | 0 | For |
| Vestal Point Capital, LP | 983,720 | 0 | 0 | 0 | For |
| Charles Schwab | 936,594 | 0 | 0 | 0 | For |
| Janus Henderson | 916,051 | 0 | 0 | 0 | For |
| Vanguard | 775,155 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 739,730 | 0 | 0 | 0 | For |
| Victory Capital | 700,136 | 0 | 0 | 0 | For |
| Swedbank Robur Fonder AB | 0 | 567,629 | 0 | 0 | Against |
| GW&K Investment Management, LLC | 559,141 | 0 | 0 | 0 | For |
| PRIMECAP MANAGEMENT CO/CA/ | 493,040 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 479,056 | 0 | 0 | 0 | For |
| AllianceBernstein | 475,830 | 0 | 0 | 0 | For |
| Nuveen | 435,414 | 0 | 0 | 0 | For |
| Hood River Capital Management LLC | 391,378 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 386,697 | 0 | 0 | 0 | For |
Institutional-manager reports, all 525 managers: 49,323,988 for, 4,568,635 against, 61,236 abstained, 12,691 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
93% Approved · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Neurocrine Biosciences, Inc.’s own tally for this item (“The Amended 2025 Plan was approved. • Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”): 83,880,185 for, 6,170,483 against — passed, per its Form 8-K filed May 28, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Amended 2025 Plan was approved.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 146 asset managers below reported 40,134,482 for, 150,201 against, 18,613 abstained, 98 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,879,594 | 5,801 | 0 | 0 | For |
| BlackRock | 7,355,109 | 0 | 0 | 0 | For |
| Dodge & Cox | 4,419,163 | 0 | 0 | 0 | For |
| JPMorgan | 3,365,627 | 0 | 0 | 0 | For |
| Fidelity | 2,036,275 | 0 | 0 | 0 | For |
| State Street | 1,372,187 | 69 | 0 | 0 | For |
| Victory Capital | 1,303,471 | 0 | 0 | 0 | For |
| First Trust | 948,076 | 0 | 0 | 0 | For |
| Charles Schwab | 887,595 | 0 | 0 | 0 | For |
| Jackson National | 510,881 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 435,679 | 0 | 0 | 0 | For |
| AQR | 433,505 | 0 | 0 | 0 | For |
| TIAA | 416,263 | 0 | 0 | 0 | For |
| Dimensional | 265,368 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 230,456 | 0 | 0 | 0 | For |
| Equitable | 223,829 | 0 | 0 | 0 | For |
| Invesco | 220,128 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 217,899 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 204,682 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 181,727 | 0 | 0 | 0 | For |
| Allspring | 180,991 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 169,230 | 0 | 0 | 0 | For |
| Northwestern Mutual | 148,519 | 0 | 0 | 0 | For |
| Eaton Vance | 144,270 | 0 | 0 | 0 | For |
| Prudential/PGIM | 142,115 | 0 | 0 | 0 | For |
Showing the 25 largest of 146 asset managers. All 146 are in the interactive database (link above).
Not shown here: this season’s fund filings also report 1 item from the meeting of May 21, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 100,600,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 10.82% |
| 2 | BlackRock | 7.31% |
| 3 | Dodge & Cox | 4.39% |
| 4 | JPMorgan | 3.35% |
| 5 | Fidelity | 2.02% |
| 6 | State Street | 1.36% |
| 7 | Victory Capital | 1.30% |
| 8 | First Trust | 0.94% |
| 9 | Charles Schwab | 0.88% |
| 10 | Jackson National | 0.51% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Dodge & Cox | 5.16% |
| 2 | BlackRock | 4.93% |
| 3 | State Street | 3.92% |
| 4 | AQR | 2.76% |
| 5 | Two Sigma | 2.12% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 2.11% |
| 7 | BNP Paribas Asset Management Holding S.A. | 1.39% |
| 8 | Wellington | 1.13% |
| 9 | Northern Trust | 1.09% |
| 10 | RTW INVESTMENTS, LP | 1.06% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 13,385,607 | 13.31% | Form 13F, quarter ended March 31, 2026 |
| The Vanguard Group | 10,129,687 | 10.07% | Proxy statement (DEF 14A), proxy filed April 15, 2026 |
| Dodge & Cox | 5,534,624 | 5.50% | Proxy statement (DEF 14A), proxy filed April 15, 2026 |
| JPMorgan Chase | 5,442,067 | 5.41% | Form 13F, quarter ended March 31, 2026 |
| State Street | 4,354,526 | 4.33% | Form 13F, quarter ended March 31, 2026 |
| Two Sigma | 3,060,570 | 3.04% | Form 13F, quarter ended March 31, 2026 |
| Renaissance Technologies | 2,418,897 | 2.40% | Form 13F, quarter ended March 31, 2026 |
| Kevin C. Gorman, Ph.D. | 1,572,104 | 1.56% | Proxy statement (DEF 14A), proxy filed April 15, 2026 |
| Wellington Management | 1,389,539 | 1.38% | Form 13F, quarter ended March 31, 2026 |
| Kyle W. Gano, Ph.D. | 635,601 | 0.63% | Proxy statement (DEF 14A), proxy filed April 15, 2026 |
Percentages above are of 100,600,000 shares outstanding, as reported by Neurocrine Biosciences, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Neurocrine Biosciences, Inc.'s shareholder meeting held May 27, 2026, in the 2025-2026 proxy season, 639 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 4,738 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Advisory vote on the compensation paid to the Company's named executive officers; — Neurocrine Biosciences, Inc.'s filing reports the proposal as approved, with 93% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Neurocrine Biosciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 28, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Neurocrine Biosciences, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Neurocrine Biosciences, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Neurocrine Biosciences (NBIX) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/neurocrine-biosciences-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.